StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)

Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –

Neurocrine Biosciences price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Neurocrine Biosciences's price to book ratio was 4.8× on Nov 11, 2026, against 5.1× a year earlier. Over the last 5 years it ranged from 3.9× to 7.9×, with a median of 5.7×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.8×+0.1
2025Dec 31, 20254.7×−0.4
2024Dec 31, 20245.1×−1.4
2023Dec 29, 20236.5×−1.0
2022Dec 30, 20227.4×+1.4
2021Dec 31, 20216.0×−5.1
2020Dec 31, 202011.1×−6.1
2019Dec 31, 201917.2×+2.8
2018Dec 31, 201814.5×−5.3
2017Dec 29, 201719.8×+10.2
2016Dec 30, 20169.6×−1.3
2015Dec 31, 201510.9×+3.3
2014Dec 31, 20147.6×+2.7
2013Dec 31, 20134.9×+1.4
2012Dec 31, 20123.5×−4.7
2011Dec 30, 20118.1×−67.5
2010Dec 31, 201075.6×–

More Neurocrine Biosciences figures

See a number that looks wrong?